Form 4: Century Therapeutics SVP Sells Shares for Tax Withholding

Douglas Carr, SVP Finance & Operations at Century Therapeutics, sold 257 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Summary

• Douglas Carr, SVP Finance & Operations at Century Therapeutics, Inc. (IPSC), reported the sale of 257 shares of common stock.
• The transaction occurred on December 8, 2025, at a price of $0.532 per share.
• The sale was automatic and not at the discretion of Mr. Carr, executed solely to cover tax withholding obligations associated with the vesting of restricted stock units.
• Following this transaction, Mr. Carr directly beneficially owns 404,874 shares of common stock.

Sentiment

Score: 5

Explanation: The transaction is a routine, non-discretionary sale to cover tax obligations, which is neutral in terms of company sentiment and does not reflect a change in insider confidence or company fundamentals.

Positives

• The sale was a non-discretionary transaction by the insider, specifically for covering tax obligations, which is a routine and expected event.

Negatives

• A minor reduction in insider ownership, though for a non-discretionary tax purpose rather than a voluntary sale.

Future Outlook

NA

Industry Context

This is a routine insider transaction related to tax obligations and does not provide specific insights into broader industry trends or the competitive landscape for Century Therapeutics.

Stakeholder Impact

• Shareholders: Minimal impact due to the small number of shares sold and the non-discretionary nature of the transaction, which is a common occurrence for executives receiving equity compensation.
• Employees: No direct impact on employees.

Key Dates

Keywords

Century Therapeutics, IPSC, Douglas Carr, Form 4, Insider Transaction, Stock Sale, Tax Withholding, Restricted Stock Units, SVP Finance & Operations